What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma?

Riccardo Lencioni

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Image-guided tumour ablation is recommended in patients with early-stage hepatocellular carcinoma (HCC) when surgical options are precluded. Radiofrequency ablation (RFA) has shown superior anticancer effect and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta-analyses of randomised controlled trials, and is currently established as the standard method for local tumour treatment. Novel thermal and non-thermal techniques for tumour ablation seem to have potential to overcome the limitations of RFA and warrant further clinical investigation. The recent addition of molecular targeted drugs with anti-angiogenic and antiproliferative properties to the therapeutic armamentarium for HCC has prompted the design of clinical trials aimed at investigating the synergies between local ablation and systemic treatments. The outcomes of these trials are eagerly awaited, as they have the potential to revolutionize the treatment of HCC.

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Primary Liver Cancer
PublisherWiley-Blackwell
Pages142-148
Number of pages7
ISBN (Print)9780470657973
DOIs
StatePublished - Nov 29 2011
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Ablation Techniques
Neoplasms
Angiogenesis Inhibitors
Therapeutics
Meta-Analysis
Ethanol
Randomized Controlled Trials
Hot Temperature
Clinical Trials
Injections
Survival

Keywords

  • Combination therapy
  • Ethanol injection
  • Radiofrequency ablation
  • Sorafenib

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lencioni, R. (2011). What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma? In Clinical Dilemmas in Primary Liver Cancer (pp. 142-148). Wiley-Blackwell. https://doi.org/10.1002/9781119962205.ch20

What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma? / Lencioni, Riccardo.

Clinical Dilemmas in Primary Liver Cancer. Wiley-Blackwell, 2011. p. 142-148.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lencioni, R 2011, What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma? in Clinical Dilemmas in Primary Liver Cancer. Wiley-Blackwell, pp. 142-148. https://doi.org/10.1002/9781119962205.ch20
Lencioni R. What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma? In Clinical Dilemmas in Primary Liver Cancer. Wiley-Blackwell. 2011. p. 142-148 https://doi.org/10.1002/9781119962205.ch20
Lencioni, Riccardo. / What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma?. Clinical Dilemmas in Primary Liver Cancer. Wiley-Blackwell, 2011. pp. 142-148
@inbook{192ff2d36e404b0ba44185255decb8c5,
title = "What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma?",
abstract = "Image-guided tumour ablation is recommended in patients with early-stage hepatocellular carcinoma (HCC) when surgical options are precluded. Radiofrequency ablation (RFA) has shown superior anticancer effect and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta-analyses of randomised controlled trials, and is currently established as the standard method for local tumour treatment. Novel thermal and non-thermal techniques for tumour ablation seem to have potential to overcome the limitations of RFA and warrant further clinical investigation. The recent addition of molecular targeted drugs with anti-angiogenic and antiproliferative properties to the therapeutic armamentarium for HCC has prompted the design of clinical trials aimed at investigating the synergies between local ablation and systemic treatments. The outcomes of these trials are eagerly awaited, as they have the potential to revolutionize the treatment of HCC.",
keywords = "Combination therapy, Ethanol injection, Radiofrequency ablation, Sorafenib",
author = "Riccardo Lencioni",
year = "2011",
month = "11",
day = "29",
doi = "10.1002/9781119962205.ch20",
language = "English (US)",
isbn = "9780470657973",
pages = "142--148",
booktitle = "Clinical Dilemmas in Primary Liver Cancer",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - What is the Future of Image-Guided Radiofrequency Ablation for Hepatocellular Carcinoma?

AU - Lencioni, Riccardo

PY - 2011/11/29

Y1 - 2011/11/29

N2 - Image-guided tumour ablation is recommended in patients with early-stage hepatocellular carcinoma (HCC) when surgical options are precluded. Radiofrequency ablation (RFA) has shown superior anticancer effect and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta-analyses of randomised controlled trials, and is currently established as the standard method for local tumour treatment. Novel thermal and non-thermal techniques for tumour ablation seem to have potential to overcome the limitations of RFA and warrant further clinical investigation. The recent addition of molecular targeted drugs with anti-angiogenic and antiproliferative properties to the therapeutic armamentarium for HCC has prompted the design of clinical trials aimed at investigating the synergies between local ablation and systemic treatments. The outcomes of these trials are eagerly awaited, as they have the potential to revolutionize the treatment of HCC.

AB - Image-guided tumour ablation is recommended in patients with early-stage hepatocellular carcinoma (HCC) when surgical options are precluded. Radiofrequency ablation (RFA) has shown superior anticancer effect and greater survival benefit with respect to the seminal percutaneous technique, ethanol injection, in meta-analyses of randomised controlled trials, and is currently established as the standard method for local tumour treatment. Novel thermal and non-thermal techniques for tumour ablation seem to have potential to overcome the limitations of RFA and warrant further clinical investigation. The recent addition of molecular targeted drugs with anti-angiogenic and antiproliferative properties to the therapeutic armamentarium for HCC has prompted the design of clinical trials aimed at investigating the synergies between local ablation and systemic treatments. The outcomes of these trials are eagerly awaited, as they have the potential to revolutionize the treatment of HCC.

KW - Combination therapy

KW - Ethanol injection

KW - Radiofrequency ablation

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84886352996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886352996&partnerID=8YFLogxK

U2 - 10.1002/9781119962205.ch20

DO - 10.1002/9781119962205.ch20

M3 - Chapter

SN - 9780470657973

SP - 142

EP - 148

BT - Clinical Dilemmas in Primary Liver Cancer

PB - Wiley-Blackwell

ER -